News

A multidisciplinary approach to care is key when addressing sexual health concerns among breast cancer survivors.

Mark S. Lin, MSN, FNP-BC, highlighted nursing considerations for breast reconstruction surgery in breast cancer.

Lillian Rodich, PA-C, MPH, stressed that nurses can take advantage of accessible and local integrative medicine resources to treat patients with cancer.

Don S. Dizon, MD, FACP, FASCO, shared insights on what pregnancy looks like with a breast cancer diagnosis and what those considering pregnancy should know.

Findings from real-world community clinics show favorable efficacy of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer.

The FDA issued a complete response letter to retifanlimab due to inspection findings at a third-party facility.

Tazemetostat has been withdrawn from the market for all approved indications following safety data conveying secondary hematologic malignancy risk.

Samantha Shenoy, NP, MSN, provides nursing guidance on teclistamab/subcutaneous daratumumab’s second-line approval in multiple myeloma.

Patricia Jakel, MN, RN, AOCN, shares how personal and professional experience impact her view on testing even beyond what is recommended.

Data show that sentinel lymph node biopsy is becoming less routine for older women with breast early stage HR-positive, HER2-negative breast cancer.

A significant portion of patients with locally advanced breast cancer receiving ultra-hypofractionation radiotherapy responded to treatment.

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04.

Teclistamab plus daratumumab hyaluronidase-fihj has been approved for patients with relapsed/refractory multiple myeloma as part of the CNPV program.

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger age groups with mccRCC.

Abiraterone/prednisone plus olaparib improves survival outcomes vs monotherapy or sequential use in BRCA1/2- or ATM-altered mCRPC.

Explore safety and efficacy findings from KEYNOTE-B15/EV-304, LITESPARK-011, and more from the ASCO Genitourinary Cancers Symposium.

An early but temporary decline in QOL followed by later cognitive effects and pain was seen in patients with RCC receiving adjuvant durvalumab/tremelimumab.

Jacqueline Redeemer, RN, MN, AOCNS, discusses the integration of safe handling practices for oncology nurses and APPs across the oncology continuum.

Adding 177Lu-PSMA-617 to ADT and an ARPI maintained health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

With the addition of pembrolizumab to standard androgen deprivation therapy and radiation, immune-related adverse events are more likely.

Phase 3 LITESPARK-011 trial results demonstrated PFS and ORR benefits with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC after ICI therapy.

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases.

Neoadjuvant EV plus pembrolizumab significantly improved event-free survival and overall survival vs gemcitabine/cisplatin in the phase 3 KEYNOTE-B15 trial.

ONS is developing a collection of photos of dermatologic toxicities across skin types to address disparities in the care of patients of color with cancer.

Claire Conley, PhD, and Marcelo Sleiman, Jr., discuss the need for protocols in supporting patients’ psychosocial needs.

Patients with PTEN-deficient metastatic hormone-sensitive prostate cancer had improved rPFS with capivasertib plus abiraterone.

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s National Priority Voucher pilot program.

The FDA has approved encorafenib plus cetuximab and fluorouracil-based chemotherapy in patients with BRAF V600E-positive metastatic colorectal cancer.